Evidence map›Paper›PMID 30424010›Full record

ReviewMedical sciences (Basel, Switzerland)2018

Theranostics Applications of Nanoparticles in Cancer Immunotherapy.

Yihai Liu, Xixi Wang, Mubashir Hussain, Mu Lv, Xiaohan Dong, Tianying Wang, Xueqin Xu, Bin Liu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Medical sciences (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Current applications of nanomaterials in urinary system tumors.Frontiers in bioengineering and biotechnology · 2023
    Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Recent advances in nanotheranostics for triple negative breast cancer treatment.Journal of experimental & clinical cancer research : CR · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yihai LiuDepartment of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. lyh1204913205@gmail.com.
Xixi WangDepartment of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. wxxwq666@163.com.
Mubashir HussainState Key Laboratory of Bioelectronics, School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, China. mubashir_tuf@hotmail.com.ORCID 0000-0002-1673-7109
Mu LvDepartment of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. 15651738713@163.com.
Xiaohan DongDepartment of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. xiaohantung@163.com.
Tianying WangDepartment of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. wty0118@icloud.com.
Xueqin XuDepartment of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. jiuajiu9@outlook.com.
Bin LiuDepartment of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing 211166, China. liubin@njmu.edu.cn.ORCID 0000-0003-3477-3178

Funding

Natural Science Foundation of Jiangsu Province BK20140900NSFC 61401217NSFC 61527806
6 · The paper itself

Abstract

With the advancement in the mechanism of immune surveillance and immune evasion in cancer cells, cancer immunotherapy shows promising results for treating cancer with established efficacy and less toxicity. As a result of the off-target effect, the approach for delivering vaccines, adjuvants, or antibodies directly to tumor sites is gaining widespread attention. An effective alternative is to utilize nanoengineered particles, functioning as drug-delivery systems or as antigens themselves. This article reviews the practical implementation of nanotechnology in cancer immunotherapy.

Indexed as

cancerimmune evasionimmunotherapynanoparticles

Identifiers

PMID30424010
PMCPMC6313674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.